Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.

You are here:Home-Chemical Inhibitors & Agonists-Cell Cycle/DNA Damage-ATM/ATR-XRD-0394 hydrochloride
XRD-0394 hydrochloride

Chemical Structure : XRD-0394 hydrochloride

CAS No.: 2595308-11-3

XRD-0394 hydrochloride (XRD0394 hydrochloride)

Catalog No.: PC-22114Not For Human Use, Lab Use Only.

XRD-0394 hydrochloride (XRD0394) is a potent, specific, orally bioavailable dual inhibitor of DNA damage-response kinases ATM and DNA-PK with IC50 of 0.39 and 0.89 nM, respectively.

Packing Price Stock Quantity
25 mg Get quote
50 mg Get quote
100 mg Get quote
250 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC)

Biological Activity

XRD-0394 hydrochloride (XRD0394) is a potent, specific, orally bioavailable dual inhibitor of DNA damage-response kinases ATM and DNA-PK with IC50 of 0.39 and 0.89 nM, respectively.
XRD-0394 is >100-fold selective for ATM and DNA-PK versus mTOR, PI3Kβ, ATR and SMG-1 and > 40-fold selective versus PI3Kγ and PI3Kδ, and 14-fold selective versus PI3Kα.
XRD-0394 inhibits phosphorylation by ATM and DNA-PK kinases, but not structurally related kinases, in human tumor cell.
XRD-0394 shows both significantly greater radiosensitization and less cellular toxicity in the absence of IR when compared to a specific ATR inhibitor, RP3500.
XRD-0394 also potentiates the effectiveness of topoisomerase I inhibitors in vitro.
XRD-0394 shows single agent activity and synergy in combination with PARP inhibitors in cells lacking BRCA1/2.

Physicochemical Properties

M.Wt 564.07
Formula C26H31ClFN5O4S
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

N-(5-(7'-fluoro-3'-methyl-2'-oxo-2',3'-dihydrospiro[cyclobutane-1,1'-pyrrolo[2,3-c]quinolin]-8'-yl)-2-(2-(isopropylamino)ethoxy)pyridin-3-yl)methanesulfonamide hydrochloride

References

1. Gilmer TM, et al. Mol Cancer Ther. 2024 Apr 8. doi: 10.1158/1535-7163.MCT-23-0890.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: